Cytosorbents Statistics
Total Valuation
Cytosorbents has a market cap or net worth of $29.01 million. The enterprise value is $53.47 million.
Important Dates
The last earnings date was Wednesday, May 13, 2026, after market close.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytosorbents has 62.70 million shares outstanding. The number of shares has increased by 12.01% in one year.
| Current Share Class | 62.70M |
| Shares Outstanding | 62.70M |
| Shares Change (YoY) | +12.01% |
| Shares Change (QoQ) | -0.10% |
| Owned by Insiders (%) | 12.26% |
| Owned by Institutions (%) | 26.34% |
| Float | 55.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.78 |
| Forward PS | 0.94 |
| PB Ratio | 13.23 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 13.34.
| Current Ratio | 1.09 |
| Quick Ratio | 0.73 |
| Debt / Equity | 13.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.68 |
Financial Efficiency
Return on equity (ROE) is -141.58% and return on invested capital (ROIC) is -22.94%.
| Return on Equity (ROE) | -141.58% |
| Return on Assets (ROA) | -18.33% |
| Return on Invested Capital (ROIC) | -22.94% |
| Return on Capital Employed (ROCE) | -55.22% |
| Weighted Average Cost of Capital (WACC) | 9.93% |
| Revenue Per Employee | $288,372 |
| Profits Per Employee | -$91,845 |
| Employee Count | 129 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 2.88 |
Taxes
| Income Tax | -401,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.25% in the last 52 weeks. The beta is 1.44, so Cytosorbents's price volatility has been higher than the market average.
| Beta (5Y) | 1.44 |
| 52-Week Price Change | -45.25% |
| 50-Day Moving Average | 0.59 |
| 200-Day Moving Average | 0.74 |
| Relative Strength Index (RSI) | 29.48 |
| Average Volume (20 Days) | 92,877 |
Short Selling Information
The latest short interest is 2.04 million, so 3.26% of the outstanding shares have been sold short.
| Short Interest | 2.04M |
| Short Previous Month | 2.04M |
| Short % of Shares Out | 3.26% |
| Short % of Float | 3.71% |
| Short Ratio (days to cover) | 27.78 |
Income Statement
In the last 12 months, Cytosorbents had revenue of $37.20 million and -$11.85 million in losses. Loss per share was -$0.19.
| Revenue | 37.20M |
| Gross Profit | 26.41M |
| Operating Income | -13.40M |
| Pretax Income | -12.25M |
| Net Income | -11.85M |
| EBITDA | -11.92M |
| EBIT | -13.40M |
| Loss Per Share | -$0.19 |
Full Income StatementBalance Sheet
The company has $4.81 million in cash and $29.28 million in debt, with a net cash position of -$24.46 million or -$0.39 per share.
| Cash & Cash Equivalents | 4.81M |
| Total Debt | 29.28M |
| Net Cash | -24.46M |
| Net Cash Per Share | -$0.39 |
| Equity (Book Value) | 2.19M |
| Book Value Per Share | 0.03 |
| Working Capital | 1.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$10.07 million and capital expenditures -$173,000, giving a free cash flow of -$10.25 million.
| Operating Cash Flow | -10.07M |
| Capital Expenditures | -173,000 |
| Depreciation & Amortization | 1.48M |
| Net Borrowing | 2.48M |
| Free Cash Flow | -10.25M |
| FCF Per Share | -$0.16 |
Full Cash Flow StatementMargins
Gross margin is 71.01%, with operating and profit margins of -36.01% and -31.85%.
| Gross Margin | 71.01% |
| Operating Margin | -36.01% |
| Pretax Margin | -32.93% |
| Profit Margin | -31.85% |
| EBITDA Margin | -32.04% |
| EBIT Margin | -36.01% |
| FCF Margin | n/a |
Dividends & Yields
Cytosorbents does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.01% |
| Shareholder Yield | -12.01% |
| Earnings Yield | -40.85% |
| FCF Yield | -35.32% |
Analyst Forecast
The average price target for Cytosorbents is $5.25, which is 1,034.89% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.25 |
| Price Target Difference | 1,034.89% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 42.98% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 5, 2014. It was a reverse split with a ratio of 1:25.
| Last Split Date | Dec 5, 2014 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |
